SCHEMBL4412983

SCHEMBL4412983

COc1ccc2cc(C(=O)NCCCCCCN(NC(=O)[C@@H](N)CC(C)C)C(=O)C(F)(F)F)c(=O)oc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ CA12 O43570 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA4 P22748 3/20 0.46
▸ CA7 P43166 3/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA5A P35218 2/20 0.46
▸ CA5B Q9Y2D0 2/20 0.46
▸ AKR1B10 O60218 1/20 0.46
▸ AKR1B1 P15121 1/20 0.46
▸ KDM4E B2RXH2 4/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ HPGD P15428 4/20 0.45
▸ HSD17B10 Q99714 3/20 0.45
▸ GLA P06280 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ MAOB P27338 4/20 0.45
▸ RAB9A P51151 2/20 0.44
▸ TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4412980 0.82 NPC1 (0.48) NPC1RXFP1CA12CA2CA4
SCHEMBL6517660 0.80 AKR1B10 (0.52) NPC1RXFP1CA12CA2CA4
SCHEMBL13521823 0.74 NPC1 (0.62) NPC1RXFP1CA12CA2CA4
SCHEMBL1415893 0.70 NPC1 (0.69) NPC1RXFP1CA12CA2CA4
SCHEMBL12221078 0.68 ALDH1A1 (0.61) NPC1RXFP1CA12CA2CA4
SCHEMBL19158900 0.68 NPC1 (0.56) NPC1RXFP1CA12CA2CA4
SCHEMBL10305767 0.67 NPC1 (0.77) NPC1RXFP1CA12CA2CA4
SCHEMBL17999230 0.66 ALDH1A1 (0.71) NPC1RXFP1CA12CA2CA4
SCHEMBL25707982 0.66 ALDH1A1 (0.65) NPC1RXFP1CA12CA2CA4
SCHEMBL29233559 0.65 CYP2D6 (0.84) KDM4EALDH1A1HPGDHSD17B10GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1691845-A4 COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE BRISTOL MYERS SQUIBB PHARMA CO (US) 2009-02-25 — — EP disclosed
EP-1691845-A1 COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE Bristol-Myers Squibb Pharma Company (US) 2006-08-23 — — EP disclosed
US-20050106100-A1 Compounds containing matrix metalloproteinase substrates and methods of their use LANTHEUS MEDICAL IMAGING, INC. 2005-05-19 — — US disclosed
WO-2005023314-A1 COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050106100-A1 Compounds containing matrix metalloproteinase substrates and methods of their use MMP1, MMP10, MMP8 NPC1 1358/4885RXFP1 2548/4885CA12 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback